Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 3/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 2/20 | 0.36 |
| ▸ | UGCG | Q16739 | 2/20 | 0.36 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23567326 | 1.00 | TSHR (0.44) | TSHRL3MBTL1TDP1NAAAHRH4 | |
| SCHEMBL23567301 | 1.00 | TSHR (0.44) | TSHRL3MBTL1TDP1NAAAHRH4 | |
| SCHEMBL23567217 | 1.00 | TSHR (0.44) | TSHRL3MBTL1TDP1NAAAHRH4 | |
| SCHEMBL23567240 | 1.00 | TSHR (0.44) | TSHRL3MBTL1TDP1NAAAHRH4 | |
| SCHEMBL23567238 | 1.00 | TSHR (0.44) | TSHRL3MBTL1TDP1NAAAHRH4 | |
| SCHEMBL23567311 | 0.98 | TSHR (0.45) | TSHRL3MBTL1TDP1NAAAHRH4 | |
| SCHEMBL23567268 | 0.93 | TSHR (0.47) | TSHRL3MBTL1TDP1NAAAHRH4 | |
| SCHEMBL23014897 | 0.92 | L3MBTL1 (0.50) | TSHRL3MBTL1TDP1NAAAHRH4 | |
| SCHEMBL1422059 | 0.92 | L3MBTL1 (0.50) | TSHRL3MBTL1TDP1NAAAHRH4 | |
| SCHEMBL1421766 | 0.92 | L3MBTL1 (0.50) | TSHRL3MBTL1TDP1NAAAHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113024359-B | Process for preparing alkoxymethyl alkynyl ether compounds having terminal triple bonds | 信越化学工业株式会社 | 2024-06-11 | — | — | CN | disclosed |
| EP-3842406-B1 | PROCESS FOR PREPARING AN ALKOXYMETHYL ALKYNYL ETHER COMPOUND HAVING A TERMINAL TRIPLE BOND | SHINETSU CHEMICAL CO (JP) | 2023-10-11 | — | — | EP | disclosed |
| US-11384041-B2 | Process for preparing an alkoxymethyl alkynyl ether compound having a terminal triple bond | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2022-07-12 | — | — | US | disclosed |
| US-20210198172-A1 | PROCESS FOR PREPARING AN ALKOXYMETHYL ALKYNYL ETHER COMPOUND HAVING A TERMINAL TRIPLE BOND | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2021-07-01 | — | — | US | disclosed |
| EP-3842406-A1 | PROCESS FOR PREPARING AN ALKOXYMETHYL ALKYNYL ETHER COMPOUND HAVING A TERMINAL TRIPLE BOND | Shin-Etsu Chemical Co., Ltd. (JP) | 2021-06-30 | — | — | EP | disclosed |
| CN-113024359-A | Method for producing alkoxymethyl alkynyl ether compounds having terminal triple bond | 信越化学工业株式会社 | 2021-06-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198172-A1 | PROCESS FOR PREPARING AN ALKOXYMETHYL ALKYNYL ETHER COMPOUND HAVING A TERMINAL TRIPLE BOND | CBR3, CBR1, AOC2 | TSHR 2045/4885L3MBTL1 2701/4885TDP1 3814/4885 |
| US-11384041-B2 | Process for preparing an alkoxymethyl alkynyl ether compound having a terminal triple bond | CBR3, CBR1, AOC2 | TSHR 2045/4885L3MBTL1 2701/4885TDP1 3814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.